참고문헌
- Bukhari MH, Niazi S, Anwar M, Chaudhry NA, Naeem S (2008). Prognostic significance of new immunohistochemistry scoring of p53 protein expression in cutaneous squamous cell carcinoma of mice. Ann N Y Acad Sci, 1138, 1-9. https://doi.org/10.1196/annals.1414.001
- Castel V, Segura V, Berlanga P (2013). Emerging drugs for neuroblastoma. Expert Opin Emerg Drugs, 18, 155-71. https://doi.org/10.1517/14728214.2013.796927
- Cheung R (2012). Poor treatment outcome of neuroblastoma and other peripheral nerve cell tumors may be related to under usage of radiotherapy and socio-economic disparity: a US SEER data analysis. Asian Pac J Cancer Prev, 13, 4587-91. https://doi.org/10.7314/APJCP.2012.13.9.4587
- Chung YS, Maeda K, Sowa M (1996). Prognostic value of angiogenesis in gastro-intestinal tumours. Eur J Cancer, 32, 2501-5. https://doi.org/10.1016/S0959-8049(96)00382-6
- Davidoff AM, Pence JC, Shorter NA, Iglehart JD, Marks JR (1992). Expression of p53 in human neuroblastoma- and neuroepithelioma-derived cell lines. Oncogene, 7, 127-33.
- Del Carmen Mejia M, Navarro S, Pellin A, et al (2002). Study of proliferation and apoptosis in neuroblastoma. Their relation with other prognostic factors. Arch Med Res, 33, 466-72. https://doi.org/10.1016/S0188-4409(02)00384-3
- Ferrara N (2002). VEGF and the quest for tumour angiogenesis factors. Nat Rev Cancer, 2, 795-803. https://doi.org/10.1038/nrc909
- Ferrara N, Gerber HP, LeCouter J (2003). The biology of VEGF and its receptors. Nat Med, 9, 669-76. https://doi.org/10.1038/nm0603-669
- Goldhirsch A, Ingle JN, Gelber RD, et al (2009). Thresholds for therapies: highlights of the St Gallen International Expert Consensus on the primary therapy of early breast cancer 2009. Ann Oncol, 20, 1319-29. https://doi.org/10.1093/annonc/mdp322
- Hollstein M, Sidransky D, Vogelstein B, Harris CC (1991). p53 mutations in human cancers. Science, 253, 49-53. https://doi.org/10.1126/science.1905840
- Imamura J, Bartram CR, Berthold F, et al (1993). Mutation of the p53 gene in neuroblastoma and its relationship with N-myc amplification. Cancer Res, 53, 4053-8.
- Inandiklioglu N, Yilmaz S, Demirhan O, Erdogan S, Tanyeli A (2012). Chromosome imbalances and alterations of AURKA and MYCN genes in children with neuroblastoma. Asian Pac J Cancer Prev, 13, 5391-7. https://doi.org/10.7314/APJCP.2012.13.11.5391
- Ishola TA, Chung DH (2007). Neuroblastoma. Surg Oncol, 16, 149-56.
- Jakovljevic G, Culic S, Stepan J, Bonevski A, Seiwerth S (2009). Vascular endothelial growth factor in children with neuroblastoma: a retrospective analysis. J Exp Clin Cancer Res, 143, 1-11.
- Jin Q, Hemminki K, Enquist K, et al (2005). Vascular endothelial growth factor polymorphisms in relation to breast cancer development and prognosis. Clin Cancer Res, 11, 3647-53. https://doi.org/10.1158/1078-0432.CCR-04-1803
- Jonat W, Arnold N (2011). Is the Ki-67 labelling index ready for clinical use? Ann Oncol, 22, 500-2. https://doi.org/10.1093/annonc/mdq732
- Levine AJ, Momand J, Finlay CA (1991). The p53 tumour suppressor gene. Nature, 351, 453-6. https://doi.org/10.1038/351453a0
- Maae E, Nielsen M, Steffensen KD, et al (2011). Estimation of immunohistochemical expression of VEGF in ductal carcinomas of the breast. J Histochem Cytochem, 59, 750-60. https://doi.org/10.1369/0022155411412599
- Madjd Z, Karimi A, Molanae S, Asadi-Lari M (2011). BRCA1 protein expression level and CD44(+) phenotype in breast cancer patients. Cell J, 13, 155-62.
- Martin B, Paesmans M, Mascaux C, et al (2004). Ki-67 expression and patients survival in lung cancer: systematic review of the literature with meta-analysis. Br J Cancer, 91, 2018-25. https://doi.org/10.1038/sj.bjc.6602233
- Mehdiabadi GB, Arab E, Rafsanjani KA, Ansari S, Moinzadeh AM (2013). Neuroblastoma in Iran: an experience of 32 years at a referral childrens hospital. Asian Pac J Cancer Prev, 14, 2739-42. https://doi.org/10.7314/APJCP.2013.14.5.2739
- Mehrazma M, Madjd Z, Kalantari E, et al (2013). Expression of stem cell markers, CD133 and CD44, in pediatric solid tumors: a study using tissue microarray. Fetal Pediatr Pathol, 32, 192-204. https://doi.org/10.3109/15513815.2012.701266
- Mejia C, Navarro S, Pellin A, et al (2003). Prognostic significance of cell proliferation in human neuroblastoma: comparison with other prognostic factors. Oncol Rep, 10, 243-7.
- Mejia C, Pellin A, Navarro S, Castel V, Llombart-Bosch A (1999). A new mutation of the p53 gene in human neuroblastoma, not correlated with N-myc amplification. Int J Surgical Pathol, 7, 149-54. https://doi.org/10.1177/106689699900700304
- Meric JB (2007). Angiogenesis targeting in gastro-intestinal cancers. Bull Cancer, 94, 207-15.
- Miller CW, Simon K, Aslo A, et al (1992). p53 mutations in human lung tumors. Cancer Res, 52, 1695-8.
- Modak S, Cheung NK (2010). Neuroblastoma: Therapeutic strategies for a clinical enigma. Cancer Treat Rev, 36, 307-17. https://doi.org/10.1016/j.ctrv.2010.02.006
- Mohsenzadegan M, Madjd Z, Asgari M, et al (2013). Reduced expression of NGEP is associated with high-grade prostate cancers: a tissue microarray analysis. Cancer Immun Immunot, 62, 1609-18. https://doi.org/10.1007/s00262-013-1463-1
- Mueller S, Bhargava S, Molinaro AM, et al (2013). Poly (ADP-Ribose) polymerase inhibitor MK-4827 together with radiation as a novel therapy for metastatic neuroblastoma. Anticancer Res, 33, 755-62.
- Nikiteas NI, Tzanakis N, Theodoropoulos G, et al (2007). Vascular endothelial growth factor and endoglin (CD-105) in gastric cancer. Gastric Cancer, 10, 12-7. https://doi.org/10.1007/s10120-006-0401-8
- Osman J, Galli S, Hanafy M, Tang X, Ahmed A (2013). Identification of novel biomarkers in neuroblastoma associated with the risk for bone marrow metastasis: a pilot study. Clin Transl Oncol, 15, 953-8. https://doi.org/10.1007/s12094-013-1030-4
- Owens C, Irwin M (2012). Neuroblastoma: the impact of biology and cooperation leading to personalized treatments. Crit Rev Clin Lab Sci, 49, 85-115. https://doi.org/10.3109/10408363.2012.683483
- Patterson DM, Gao D, Trahan DN, et al (2011). Effect of MDM2 and vascular endothelial growth factor inhibition on tumor angiogenesis and metastasis in neuroblastoma. Angiogenesis, 14, 255-66. https://doi.org/10.1007/s10456-011-9210-8
- Pistoia V, Morandi F, Bianchi G, et al (2013). Immunosuppressive microenvironment in neuroblastoma. Front Oncol, 3, 1-8.
- Remvikos Y, Beuzeboc P, Zajdela A, et al (1989). Correlation of pretreatment proliferative activity of breast cancer with the response to cytotoxic chemotherapy. J Natl Cancer Inst, 81, 1383-7. https://doi.org/10.1093/jnci/81.18.1383
- Sayed-Ahmed MM, Hafez MM, Al-Shabanah OA, et al (2013). Increased expression of biological markers as potential therapeutic targets in Saudi women with triple-negative breast cancer. Tumori, 99, 545-54. https://doi.org/10.1177/030089161309900418
- Scholzen T, Gerdes J (2000). The Ki-67 protein: from the known and the unknown. J Cell Physiol, 182, 311-22. https://doi.org/10.1002/(SICI)1097-4652(200003)182:3<311::AID-JCP1>3.0.CO;2-9
- Shimada H, Ambros IM, Dehner LP, et al (1999). Terminology and morphologic criteria of neuroblastic tumors: recommendations by the International Neuroblastoma Pathology Committee. Cancer, 86, 349-63. https://doi.org/10.1002/(SICI)1097-0142(19990715)86:2<349::AID-CNCR20>3.0.CO;2-Y
- Sidell N, Koeffler HP (1988). Modulation of Mr 53,000 protein with induction of differentiation of human neuroblastoma cells. Cancer Res, 48, 2226-30.
- Taeb J, Asgari M, Abolhasani M, Farajollahi MM, Madjd Z (2014). Expression of prostate stem cell antigen (PSCA) in prostate cancer: A tissue microarray study of Iranian patients. Pathol Res Pract, 210, 18-23. https://doi.org/10.1016/j.prp.2013.09.012
- Teitz T, Inoue M, Valentine MB, et al (2013). Th-MYCN mice with caspase-8 deficiency develop advanced neuroblastoma with bone marrow metastasis. Cancer Res, 73, 4086-97. https://doi.org/10.1158/0008-5472.CAN-12-2681
- Tong QS, Zheng LD, Tang ST, et al (2008). Expression and clinical significance of stem cell marker CD133 in human neuroblastoma. World J Pediatr, 4, 58-62. https://doi.org/10.1007/s12519-008-0012-z
- Tweddle DA, Pearson AD, Haber M, et al (2003). The p53 pathway and its inactivation in neuroblastoma. Cancer Lett, 197, 93-8. https://doi.org/10.1016/S0304-3835(03)00088-0
- Wang X, Chen X, Fang J, Yang C (2013). Overexpression of both VEGF-A and VEGF-C in gastric cancer correlates with prognosis, and silencing of both is effective to inhibit cancer growth. Int J Clin Exp Pathol, 6, 586-97.
- Yamamori M, Sakaeda T, Nakamura T, et al (2004). Association of VEGF genotype with mRNA level in colorectal adenocarcinomas. Biochem Biophys Res Commun, 325, 144-50. https://doi.org/10.1016/j.bbrc.2004.10.005
- Zhang J, Liu Y, Bao P, Wang Y, Zhang Y (2013). Rare coexistence of metastatic neuroblastoma of liver and solid pseudo papillary tumor of pancreas: Case report and literature review. J Cancer Res Ther, 9, 308-10. https://doi.org/10.4103/0973-1482.113402
피인용 문헌
- Expression of Neuronal Markers, NFP and GFAP, in Malignant Astrocytoma vol.15, pp.15, 2014, https://doi.org/10.7314/APJCP.2014.15.15.6315
- Evaluation of HER-2/neu Overexpression in Gastric Carcinoma using a Tissue Microarray vol.15, pp.18, 2014, https://doi.org/10.7314/APJCP.2014.15.18.7597
- Differential Diagnosis of CT Images in Children with Neuroblastomas and Ganglioneuroblastomas vol.15, pp.23, 2015, https://doi.org/10.7314/APJCP.2014.15.23.10509
- Prognostic Factors in Oligodendrogliomas: a Clinical Study of Twenty-Five Consecutive Patients vol.16, pp.13, 2015, https://doi.org/10.7314/APJCP.2015.16.13.5319
- Negative HER2/neu Amplification Using Immunohistochemistry and Chromogenic in Situ Hybridization Techniques in Skin Melanoma Cases vol.16, pp.2, 2015, https://doi.org/10.7314/APJCP.2015.16.2.421
- MIB-1 Index as a Surrogate for Mitosis-Karyorrhexis Index in Neuroblastoma vol.39, pp.8, 2015, https://doi.org/10.1097/PAS.0000000000000478